GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OncoTherapy Science 4564.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

16

0.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥808.5m

FY2017FY2026

Net income

−¥910.6m

FY2017FY2026

Free cash flow

−¥985.0m

FY2017FY2026

Shareholders' equity

¥2.14bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥808.5m¥750.0m¥610.1m¥1.13bn¥1.15bn¥332.5m¥316.2m¥280.6m¥211.3m¥286.7m
Research and development¥534.9m¥491.1m¥678.1m¥716.5m¥1.73bn¥1.38bn¥1.74bn¥2.83bn¥2.93bn¥2.94bn
Operating income−¥810.4m−¥1.61bn−¥1.28bn−¥1.11bn−¥2.05bn−¥1.64bn−¥2.23bn−¥2.95bn−¥2.99bn−¥3.00bn
Net income−¥910.6m−¥815.3m−¥1.29bn−¥1.12bn−¥2.57bn−¥1.56bn−¥2.24bn−¥2.93bn−¥2.85bn−¥3.00bn
Diluted earnings per share-2.28-2.26-4.74-5.14-13.35-8.11-12.56-16.64-18.45-20.42

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥2.36bn¥1.16bn¥867.3m¥1.51bn¥2.69bn¥3.37bn¥5.09bn¥5.37bn¥8.02bn¥10.59bn
Cash and short-term investments¥2.09bn¥833.9m¥527.7m¥1.12bn¥1.84bn¥2.90bn¥4.71bn¥4.86bn¥6.74bn¥10.07bn
Total liabilities¥217.4m¥426.1m¥513.6m¥656.3m¥705.0m¥291.3m¥359.6m¥496.9m¥441.7m¥488.5m
Debt—¥51.1m¥106.8m———————
Shareholders' equity¥2.14bn¥729.1m¥353.7m¥855.2m¥1.98bn¥3.08bn¥4.73bn¥4.87bn¥7.32bn¥10.10bn
Shares outstanding399m361m272m218m193m193m178m176m154m147m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥922.8m−¥815.0m−¥1.23bn−¥794.9m−¥2.07bn−¥1.76bn−¥2.28bn−¥2.37bn−¥3.04bn−¥2.99bn
Capital spending−¥62.2m−¥279,000−¥2.6m−¥5.4m−¥456.9m−¥43.9m−¥131.4m−¥71.3m−¥408.9m−¥12.0m
Free cash flow−¥985.0m−¥815.3m−¥1.23bn−¥800.3m−¥2.53bn−¥1.81bn−¥2.41bn−¥2.44bn−¥3.44bn−¥3.00bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥170.8m¥211.0m¥165.6m¥230.4m¥201.5m¥186.8m¥338.0m¥125.0m
Operating income−¥285.1m−¥151.3m−¥218.8m−¥172.0m−¥303.9m−¥117.8m−¥167.0m−¥241.0m
Net income−¥288.9m−¥127.0m−¥228.5m−¥240.8m−¥314.4m−¥98.1m−¥172.0m−¥243.0m
Diluted earnings per share-0.72-0.32-0.63-0.67-0.87-0.27-0.63-0.89
Total assets¥2.61bn¥2.36bn¥2.48bn¥1.94bn¥1.53bn¥1.16bn¥1.23bn¥1.55bn
Cash and short-term investments¥2.33bn¥2.09bn¥2.19bn¥1.68bn¥1.23bn¥833.9m¥945.6m¥1.10bn
Shareholders' equity¥2.35bn¥2.14bn¥2.14bn¥1.65bn¥1.08bn¥729.1m¥828.8m¥1.00bn

Financial ratios

Data as of 9 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin-112.2%-214.5%-210.7%-97.5%-178.0%-492.7%———
Net margin-112.6%-108.7%-211.1%-98.6%-222.9%-469.7%———
Return on equity-42.5%-111.8%-364.2%-130.8%-129.9%-50.8%———
Return on assets-38.6%-70.6%-148.5%-74.0%-95.8%-46.4%———
Free cash flow yield-10.8%-11.3%-22.5%-18.1%-41.9%-44.6%———
Revenue growth7.8%22.9%-46.2%-1.6%247.0%5.1%———
Earnings growth11.7%-36.7%15.2%-56.5%64.7%-30.2%———
Current ratio13.59x3.37x2.27x2.33x4.30x16.39x———
Debt to equity———0.00x0.00x0.00x0.00x0.00x0.00x
Equity ratio90.8%63.1%40.8%56.6%73.7%91.4%———
Interest coverage-691.97x-1339.65x-5896.77x-110.63x-382.27x-10.42x———
R&D as a share of sales66.2%65.5%111.1%63.1%150.0%413.8%———
Buybacks as a share of market value-10.6%-32.8%-24.8%-13.0%0.0%-8.1%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-10.7%19.5%11.7%
Operating income-10.1%-13.1%-12.2%
Net income-6.6%-10.2%-10.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-155.2%-145.6%-177.5%-368.3%
Net margin-110.7%-125.1%-172.6%-359.0%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-7.5-8.8-5.3-4.5-3.9-8.9-9.2-5.1-6.3-11.2
Price to sales8.49.611.14.48.741.764.853.485.6117.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 500-for-1 split · 26 Sept 2013
  • 3-for-1 split · 27 Sept 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.